Intermittent Androgen Suppression in Prostate Cancer: Testosterone Levels and Its Implication

Journal of Sexual Medicine

Volumn 8, Issue 4, 2011, Pages 1218-1227

  Mearini, Luigi ^a   Zucchi, Alessandro ^a   Costantini, Elisabetta ^a   Bini, Vittorio ^a   Porena, Massimo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Continuous Androgen Suppression; Intermittent Androgen Suppression; Prostate Cancer; Quality of Life; Testosterone

Indexed keywords

ANDROGEN; BICALUTAMIDE; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; ERECTILE DYSFUNCTION; FOLLOW UP; FUNCTIONAL ASSESSMENT INVENTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL FUNCTION; SEXUAL INTERCOURSE; TESTOSTERONE BLOOD LEVEL;

EID: 79953313221     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02169.x     Document Type: Article

References (26)

1. Huggins C, Hodges CV. Studies on prostatic cancer. The effect of castration, estrogens and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
2. Furuya Y, Sato N, Akakura K, Ichikawa T, Suzuki N, Sato R. Paracrine growth stimulation of androgen-responsive Shionogi carcinoma 115 by its autonomous sublime. Cancer Res 1990;50:4979-83.
3. Sandford NL, Searle JW, Kerr JFR. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology 1984;16:406-10.
4. Bruchovsky N, Rennie PS, Goldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275-82.
5. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression of androgen-dependent tumours: Apoptosis and serum-specific antigen. Cancer 1993;71:2782-90.
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
7. Theyer G, Hamilton G. Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology 1998;52:353-9.
8. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan DL, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995;45:839-45.
9. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001;58:240-5.
10. Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G. A 10-year clinic experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003;43:233-40.
11. De La Faille A, Zerbib M, Conquy S, Amsellen-Ouazana D, Thiounn N, Flam TA, Debrè B. Intermittent androgen suppression in patients with prostate cancer. Br J Urol 2003;91:18-22.
12. Da Silva C, Bono A, Whelan P, Brasi M, Queimadelos M, Portillo D, Kirkali P, Robertson C. Phase III study of intermittent MAB vs continous MAB: International cooperative study. Eur Urol 1999;35(2 suppl.):A54.
13. Scharfoort E, Heathcote P, Lock T, Zerbib M, Dijkema H, Vergunst H, Srougi M, Newling D. Intermittent androgen suppression for the treatment of advanced prostate cancer. J Urol 2003;169(4 suppl.):A1483.
14. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55:1269-77.
15. Bales GT, Sinner MD, Kim JH, Choadk GW. Impact of intermittent androgen deprivation on quality of life. J Urol 1996;155:1069.
16. Bouchot O, Lenormand L, Karam G, Prunet D, Gaschignard N, Malinovsky JM, Buzelin JM. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000;38:543-9.
17. Kuhn JM, Abourachid H, Brucher P, Doutres JC, Fretin J, Jaupitre A, Jorest R, Lambert D, Petit J, Pin J, Blumberg J, Dufour-Esquerré F. A randomized comparison of the clinical hormonal effects of two GnRH agonist in patients with prostate cancer. Eur Urol 1997;32:397.
18. Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000;164:1891-4.
19. Crook LM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999;53:530-4.
20. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. A randomized comparison of Casodex (bicalutamide) 150 mg monotherapy vs. castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-56.
21. Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol Urol 2000;4:191-9.
22. Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients. Oncologist 2001;6:177-82.
23. Shaw G, Oliver RT. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. Surg Oncol 2009;18:275-82.
24. Borges R, Temido P, Sousa L, Azinhais P, Conceição P, Pereira B, Leão R, Retroz E, Brandão A, Cristo L, Sobral F. Metabolic syndrome and sexual (dys) function. J Sex Med 2009;6:2958-75.
25. Hernández-Mijares A, García-Malpartida K, Solá-Izquierdo E, Bañuls C, Rocha M, Gómez-Martínez MJ, Mármol R, Víctor VM. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med 2010;7:1954-64.
26. Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M. Endocrine aspects of male sexual dysfunctions. J Sex Med 2010;7:1627-56.